๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The use of antidepressants in clinical practice: focus on agomelatine

โœ Scribed by R. H. McAllister-Williams; D. S. Baldwin; P. M. Haddad; S. Bazire

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
91 KB
Volume
25
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

โœฆ Synopsis

Abstract

Objective

Agomelatine (Valdoxanยฎ) is licensed by the European Medicines Agency for the treatment of major depressive episodes in adults. The objective of this review was to consider how the drug should be used in clinical practice in particular starting, stopping and switching to and from the drug.

Methods

The existing clinical evidence was reviewed.

Results

Data suggest that when switching to agomelatine from other antidepressants consideration should be given to tapering the previous antidepressant in order to minimize the risk of the original drug causing discontinuation/withdrawal symptoms. The risk of pharmacological interactions between most antidepressants and agomelatine is low and so tapering the previous antidepressant can usually be done after agomelatine has been started. An exception is fluvoxamine which should not be concurrently prescribed with agomelatine. As agomelatine appears to cause no significant discontinuation symptoms, it can probably be stopped abruptly when treatment is completed or when switching to another antidepressant.

Conclusions

While this guidance may change as clinical evidence and experience grows, currently agomelatine appears to have a good tolerability profile and is relatively easy to use, though prescribers should note the requirement to conduct liver function tests (LFTs) in accordance with the Summary of Product Characteristics (SPC). Copyright ยฉ 2010 John Wiley & Sons, Ltd.

๐Ÿ“œ SIMILAR VOLUMES

Impact of the novel antidepressant agome
Impact of the novel antidepressant agomelatine on disturbed sleepโ€“wake cycles in depressed patients
โœ Maria-Antonia Quera-Salva; Patrick Lemoine; Christian Guilleminault ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 119 KB ๐Ÿ‘ 1 views

## Abstract ## Background Disturbance of sleepโ€“wake cycles is common in major depressive disorder (MDD), usually as insomnia, but also as hypersomnia or reduced daytime alertness. Agomelatine, an MT~1~ and MT~2~ receptor agonist and 5โ€HT~2C~ receptor antagonist, represents a novel approach in MDD,

Use of the Thin Prepยฎ Pap Testโ„ข in clini
Use of the Thin Prepยฎ Pap Testโ„ข in clinical practice
โœ Barbara J. Guidos; Suzanne M. Selvaggi ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 34 KB ๐Ÿ‘ 3 views

Both methods were analyzed to compare specimen adequacy and detection rates of cervical lesions. The TP method reduced the ''satisfactory but limited by'' rate by 97% and the unsatisfactory rate by 63%. For low-grade squamous intraepithelial lesions (LSILs), TP slides yielded 3.6% (348/9,583) as com

Molecular profiling of platinum resistan
Molecular profiling of platinum resistant ovarian cancer: Use of the model in clinical practice
โœ Olivier Gevaert; Nathalie Pochet; Frank De Smet; Toon Van Gorp; Bart De Moor; Di ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 39 KB

With great interest we read the article by Helleman et al., 1 investigating whether a gene set identified using microarrays could be used to predict platin resistance in ovarian cancer. The authors studied a training set obtained from 24 tumours that were analysed using cDNA microarrays. This set co